Beclometasone hydrofluoroalkane inhalation - 3M

Drug Profile

Beclometasone hydrofluoroalkane inhalation - 3M

Alternative Names: Beclometasone dipropionate hydrofluoroalkane inhalation - 3M; Beclometasone HFA inhalation - 3M; Beclometasone pressurised metered-dose inhalation - 3M; Beclomethasone breath-activated inhalation - 3M; Beclomethasone dipropionate hydrofluoroalkane inhalation - 3M; Beclomethasone HFA inhalation - 3M; Beclomethasone hydrofluoroalkane inhalation - 3M; HFA-134a BDP; Hydrofluoroalkane-134a beclomethasone dipropionate; Junik; Nexxair®; Qvar; Qvar Autohaler; Qvar BAI; Qvar Easi-Breathe; Qvar MDI; Qvar RediHaler; Qvarspray; Ventolair

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer 3M Pharmaceuticals; Teva Branded Pharmaceutical Products R&D
  • Class Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 08 Aug 2017 Registered for Asthma (In adolescents, In children) in USA (Inhalation)
  • 07 Aug 2017 Teva expects to launch beclometasone hydrofluoroalkane inhalation, delivered via breath-actuated inhaler, for Asthma in the first quarter of 2018
  • 03 Mar 2017 Adverse events and efficacy data from a phase III trial in Asthma presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top